Macrogenics Stock Today
| MGNX Stock | USD 2.22 0.02 0.91% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
MacroGenics is trading at 2.22 as of the 17th of March 2025; that is 0.91 percent increase since the beginning of the trading day. The stock's open price was 2.2. MacroGenics has more than 63 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. The company was incorporated in 2000 and is headquartered in Rockville, Maryland. Macrogenics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 62.76 M outstanding shares of which 5.52 M shares are now shorted by private and institutional investors with about 7.02 trading days to cover. More on MacroGenics
Moving together with MacroGenics Stock
Moving against MacroGenics Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
MacroGenics Stock Highlights
| CEO President | Scott MD |
| Thematic Ideas | (View all Themes) |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, NASDAQ Composite Total, Pharmaceutical Products, Cancer Fighters, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
| Financial Strength | |
MacroGenics (MGNX) is traded on NASDAQ Exchange in USA. It is located in 9704 Medical Center Drive, Rockville, MD, United States, 20850 and employs 339 people. MacroGenics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 139.33 M. MacroGenics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 62.76 M outstanding shares of which 5.52 M shares are now shorted by private and institutional investors with about 7.02 trading days to cover.
MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Check MacroGenics Probability Of Bankruptcy
Ownership AllocationMacroGenics maintains a total of 62.76 Million outstanding shares. The majority of MacroGenics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MacroGenics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MacroGenics. Please pay attention to any change in the institutional holdings of MacroGenics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MacroGenics Ownership Details
MacroGenics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. MacroGenics market risk premium is the additional return an investor will receive from holding MacroGenics long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.14) | |||
| Jensen Alpha | (0.58) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (2.27) |
MacroGenics Stock Against Markets
MacroGenics Corporate Executives
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Karrels | CFO, Sr. VP and Corporate Secretary | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.